Transcriptomic analysis of mammary tumor biospy from MMTV-ErbB2 transgenic mice [Docetaxlel]

The tyrosine kinase ErbB2 positive breast tumors have more aggressive tumor growth, poorer clinical outcome, and more resistance to radiotherapy, chemotherapy and hormone therapy. To identify the biomarkers for predicting the responses to chemotherapy, we treated genetically diverse F1 backcross (F1Bx) mice between C57BL/6J and FVB/N MMTV-Erbb2 transgenic mice with mammary tumor by docetaxel. Biopsies were taken in sterile conditions and processed for RNA and histological analysis before treatment. This will help us to have a better understanding of the heterogeneous response to chemotherapy and permit us to design better and more individualized (personalized) treatment strategies for human ErbB2 positive breast cancer. 50 MMTV-ErbB2 mammary tumor biopsy before treatment were analyzed by Affymetrix microarrays.